Compare General Motors Company (GM) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Motors Company vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? General Motors Company trades at $83.71 (market cap $72.87B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M). The key difference: General Motors Company is far larger — about 74.6× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and General Motors Company pays a 0.87% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold General Motors Company for 83 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| GM | MRVI | |
|---|---|---|
Market Cap | $72.87B | $977.37M |
Volume | 6,101,486 | 2,742,564 |
Sector | Consumer Cyclical | Health |
52-Week High | $90.30 | $9.00 |
52-Week Low | $57.34 | $2.83 |
Typical Hold Time | 83 Days | 0 Days |
Enterprise Value | $175.85B | $1.08B |
Dividend Yield | 0.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Motors (GM) trades at $84.00, up 1.98% today, with a bullish technical signal from moving averages. The company has beaten earnings estimates for three consecutive quarters, though revenue declined slightly in 2025. Analyst consensus is strongly positive with a $102.33 price target, but recent news highlights competitive pressures and a 5.5% drop in Q3 2026 U.S. vehicle sales.
GM faces headwinds from declining market share and weak electric vehicle demand, but cost savings from eased fuel economy rules and consistent earnings beats provide upside potential. Key risks include high debt levels and intense competition. The stock appears fundamentally undervalued on P/S and P/B metrics relative to analyst targets.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
